(MedPage Today) — FDA advisors narrowly supported accelerated approval for Sarepta Therapeutics’ investigational gene therapy for Duchenne muscular dystrophy (DMD) on Friday.
In a 8-to-6 vote, the agency’s Cellular, Tissue, and Gene Therapies…
SOURCE: MedPage Today Public Health & Policy – Read entire story here.